REYATAZ 50mg/1.5G powder for oral solution BRISTOL MYERS SQUIBB
atazanavir Indicated for: HIV-1 infection
J05AE08 Antiinfectives for systemic use | Direct acting antivirals | Protease inhibitors
letter R · page 27
atazanavir Indicated for: HIV-1 infection
J05AE08 Antiinfectives for systemic use | Direct acting antivirals | Protease inhibitors
oxaliplatin Indicated for: colorectal cancer
darunavir + cobicistat Indicated for: HIV-1 infection
remibrutinib Indicated for: chronic spontaneous urticaria
anti-D specific immunoglobulin Indicated for: immunosuppression
J06BB01 Antiinfectives for systemic use | Immunoglobulins | Specific immunoglobulins
anti-D immunoglobulin Indicated for: immunosuppression
J06BB01 Antiinfectives for systemic use | Immunoglobulins | Specific immunoglobulins
anti-D immunoglobulin Indicated for: immunosuppression
J06BB01 Antiinfectives for systemic use | Immunoglobulins | Specific immunoglobulins
diclofenac Indicated for: pain and inflammation
diclofenac Indicated for: pain and inflammation
diclofenac Indicated for: pain and inflammation
etofenamat Indicated for: pain and inflammation
etofenamat Indicated for: pain and inflammation
etofenamat Indicated for: pain and inflammation
homeopathic Indicated for: homeopathic use
carbocisteine Indicated for: respiratory disorders with viscous secretions
R05CB03 Respiratory system | Expectorants, excl. combinations with cough suppressants | Mucolytics
carbocisteine Indicated for: respiratory disorders with viscous secretions
R05CB03 Respiratory system | Expectorants, excl. combinations with cough suppressants | Mucolytics
carbocisteine Indicated for: respiratory disorders with viscous secretions
R05CB03 Respiratory system | Expectorants, excl. combinations with cough suppressants | Mucolytics
budesonide Indicated for: asthma; inflammatory bowel disease
combinations Indicated for: various therapeutic indications
xylometazoline Indicated for: nasal congestion; rhinitis